Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 4 of about 84 results

ea0089b13 | Basic Science | NANETS2022

Optical Genome Mapping: a Novel Approach to Identifying Structural Variants in Metastatic Neuroendocrine Tumors

DePietro, MD Daniel M. , BA Isabela Gatmaytan , Hunt, MD, PhD Stephan , Nadolski, MD Gregory , Woodard Abashai , Soulen, MD Michael , Gade, MD PhD Terence , Ackerman, PhD Daniel

Background: Genomic structural variants (SVs) encompass a large portion of mutations driving cancer progression, however, there is a paucity of data regarding such drivers in metastatic neuroendocrine tumor (mNET). Existing studies have focused on short-read sequencing of primary NET samples, which can detect single nucleotide variants, but are unable to identify larger SVs. Such studies have demonstrated a low rate of genetic mutations. Optical genome mapping (OGM) represents...
0 shares

ea0089c35 | Clinical – Surgery/Applied Pathology | NANETS2022

Liver Directed Therapy is Associated with Improved Survival in Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms with Concurrent Bone Metastasis

Limbach, MD Kristen E. , Mahuron, MD Kelly M. , Ituarte, PhD Philip H. G. , Kessler, MD Jonathan , Li, MD Daneng , Singh, MD Gagandeep

Background: Bone metastasis from gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) was once considered rare, but prevalence has recently been reported as high as 12%. Although bone metastasis has been associated with poor prognosis, the most frequent cause of mortality in this population remains liver failure when liver metastases are present. Thus, it remains unclear whether patients with concurrent liver and bone metastasis who receive liver directed therapy (LDT) w...
0 shares

ea0089c39 | Clinical – Surgery/Applied Pathology | NANETS2022

Have We Accounted for Asians? A Critical Analysis of Racial Cancer Disparity Amongst Asian Pancreatic Neuroendocrine Tumor Patients

E McElroy, MD Katherine , Irfan, MD Ahmer , Reddy, MD Sushanth , Yates, PhD Clayton , Chen, MD, FACS Herbert , Bart Rose, MD J.

Background: Pancreatic neuroendocrine tumors (pNETs) are slow growing, malignant tumors that show different survival outcomes by race. They are often diagnosed in late stages, with few treatments available. PNETs are the second most common pancreatic cancer and are rapidly increasing in incidence. Current size-based guidelines were largely developed in White patients and recently have been called into question for Black patients. We investigated differences of primary tumor si...
0 shares

ea0098c32 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

Myelodysplasia and leukemia instances after PRRT: Experience from a tertiary institution

Trikalinos, MD Nikolaos , De La Iglesia, MD Michael , Prasad MD, PhD Vikas , Amin, MD Manik , Winter, BSN, RN Kyle , Schutte MSN, FNP-C, AOCNP Justin , Kim, MD Hyun

Background: Peptide receptor radionuclide therapy (PRRT) was introduced in 2018 as one of the major advances in treatment of patients with neuroendocrine neoplasms (NENs). Initial results from the NETTER-1 trial suggested a very low percentage of secondary hematological malignancies, including myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). We sought to confirm that data in a large institutional database. Methods: Under an institutio...
0 shares

ea0098t4 | Trials In Progress | NANETS2023

Phase 2, multicenter, open-label basket trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1/2 (PRECISION I)

Iyer, MD Gopa , Demeure, MD Michael J. , Ding, MS, MA Li , Schmid, PhD Anita N. , Navarro, MD Willis , Kwiatkowski, MD, PhD David J. , Rodon Ahnert, MD, PhD Jordi

Background: nab-Sirolimus, approved in the US for patients with advanced malignant PEComa, is a novel albumin-bound mTOR inhibitor (mTORi) that inhibits the mTOR pathway via suppression of the mTORC1 complex. When TSC1 or TSC2 is inactivated via mutation or loss, the mTOR pathway may be aberrantly activated. TSC1 and TSC2 alterations occur in a range of common cancers. Clinically, in the AMPECT exploratory analysis of nab-sirolimus in advanced malignant PEComa (NCT02494570), 8...
0 shares

ea0098t12 | Trials In Progress | NANETS2023

Neuroendocrine tumors AI-based clinical trial search tool eases clinical trial discovery for patients and health care professionals

Mailman Josh , Ralic Danielle , del Rivero MD Jaydira , Gericke MD Germo , Halfdanarson MD Thorvardur R. , Herrmann MD Ken , Hollander Ronald , Albert Fisher Jr. MD George

Background: Finding relevant neuroendocrine tumor (NET) trials remains a challenge for patients and healthcare professionals (HCPs). Clinicaltrials.gov’s taxonomy associates many conditions with NETs, complicating the discovery process. As of 6/30/23 clinicaltrials.gov listed 700 recruiting, phase 1-3 interventional trials using the terms Neuroendocrine Tumors, Pheochromocytoma, and Paraganglioma. Many of these trials are not relevant for patients with NETs. Even with sev...
0 shares

ea0089c6 | Clinical – Chemo/SSA/Biologics | NANETS2022

An Open-Label, Phase 1b/2 study of Surufatinib in Combination with Tislelizumab in Patients with Advanced Neuroendocrine Tumors

Eads, MD Jennifer R. , Das, MD Satya , Li, MD Daneng , Mohamed, MD Amr , Tucci, MBS, CCRP Christopher , Nanda, MS Shivani , Kauh, MD, FACP John S. , Kania, MD, MBA Marek K. , Dasari, MD Arvind

Background: Surufatinib, an oral small molecule tyrosine kinase inhibitor, selectively inhibits vascular endothelial growth factor receptor 1, 2, and 3; fibroblast growth factor receptor 1; and colony-stimulating factor 1 receptor. Tislelizumab is a humanized immunoglobulin G4-variant anti-programmed cell death protein-1 monoclonal antibody. Combining surufatinib and tislelizumab may have synergistic effects, where inhibition of angiogenesis and stimulation of an immune respon...
0 shares

ea0089c32 | Clinical – Surgery/Applied Pathology | NANETS2022

Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis

Ziogas, MD, MPH Ioannis A. , T. Tasoudis, MD Panagiotis , C. Borbon, MD Luis , K. Sherman, MD, FACS Scott , J. Breheny, MS, PhD Patrick , Chandrasekharan, MBBS Chandrikha , S. Dillon, MD Joseph , M. Bellizzi, MD Andrew , R. Howe, MD, FACS James

Background: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are rare, aggressive tumors with poor prognosis. The WHO 2017 classification further subdivided G3 NENs into G3 neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). Current guidelines favor medical management in most of these patients, and the role of surgical management is not well-defined. We performed a systematic literature review and meta-analysis of surgical management vs ...
0 shares

ea0089p4 | Population Science | NANETS2022

Carcinoid Heart Disease in Patients Diagnosed with Small Bowel and Lung Neuroendocrine Tumors

MD, MSc Julie Hallet , MD, MPH Katrina Duncan , MD, MPH Simron Singh , MSc Victoria Barabash , MD Shaheeda Ahmed , MD Sten Myrehaug , MD, MPH Natalie Coburn , MD, MPH Calvin Law

Background: Carcinoid heart disease (CHD) is a complication of neuroendocrine tumors (NETs). While its pathophysiology and manifestations are described, little is known about its occurrence in all patients diagnosed with NETs. We examined the occurrence of CHD and explored the use of echocardiography after diagnosis of NET.Methods: We conducted a population-based retrospective cohort study of adults diagnosed with small bowel and lung NETs (2000-2019). C...
0 shares

ea0089c21 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2022

Characterizing Bone Metastases in Patients with Well-Differentiated Neuroendocrine Neoplasms Utilizing Ga68-DOTATATE PET

Coston, MD Tucker W. , Mahadevia, MBBS Himil J. , Plante, MD Marie M. , Accurso, MD Joseph M. , Sharma, MD, MBA Akash , Johnson, MD, PhD Geoffrey B. , Ashman, MD, PhD Jonathan B. , Tuba Kendi, MD Ayse , Bassam Sonbol, MD Mohamad , Hobday, MD Timothy J. , Halfdanarson, MD Thorvardur R. , Starr, DO Jason S.

Background: Tumors of neuroendocrine origin are a rare, heterogenous group of neoplasms. Neuroendocrine neoplasms (NENs) are categorized by site of origin, differentiation status, and by grade (Ki-67 expression and/or mitotic rate), with significant prognostic variability accordingly. These tumors frequently metastasize to bone, with reported incidence between 6-12% by older SSTR imaging. Our study evaluates patients with well-differentiated tumors of neuroendocrine origin to ...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more